Business Wire

TX-MARY-KAY-INC

Share
Mary Kay Inc. Releases 2020 – 2022 Sustainability & Social Impact Report

Mary Kay Inc., a global advocate for corporate social responsibility, today released a report detailing progress on Enriching Lives Today for a Sustainable Tomorrow (ELTFAST), the brand’s global sustainability program.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214005001/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Enriching Lives Today for a Sustainable Tomorrow extends Mary Kay's vision to 2030 and beyond. (Credit: Mary Kay Inc.)

“We’re proud of the progress we’ve made on our sustainability journey so far, and we are inspired to see how our actions today will address global challenges for future generations,” said Deborah Gibbins, Chief Operating Officer at Mary Kay Inc. “Mary Kay has operations in nearly 35 countries—we consider that an accomplishment and a responsibility. Enriching Lives Today for a Sustainable Tomorrow is our roadmap for supporting our business strategy, reducing our environmental impact, and supporting communities where we operate.”

Enriching Lives Today for a Sustainable Tomorrow extends Mary Kay’s vision to 2030 and beyond. It builds a picture of what good “looks like” for Mary Kay, Independent Beauty Consultants, customers and—most importantly—the planet. Enriching Lives Today for a Sustainable Tomorrow was developed with Mary Kay’s key stakeholders and is aligned with the United Nations’ Sustainable Development Goals, making Mary Kay a key part of a global coalition to ensure a better future.

The 2020 – 2022 full report can be viewed here. An executive summary of the report is available here.

Since the launch of ELTFAST in 2020, Mary Kay has made significant progress toward its goals despite the many challenges presented by the COVID-19 epidemic. The 2022 report details its efforts since 2020—the beginning of its Decade of Action—and serves as a reaffirmation of the company’s drive to deliver sustainable change.

Business Excellence

  • Focusing on nurturing its company culture, Mary Kay garnered 13 employer / great place to work awards and was ranked #8 on list of “The Companies Employees Don’t Want to Leave,” published by Resume.io.
  • Released gender diversity data in leadership: executive team is 54% female, managers and above are 59% female, with 62% of the total workforce being female.
  • In 2021, scored 75% employee engagement, a 6% increase over the 2019 full engagement survey (This is 10% over the global average for employee engagement).
  • 38 company awards in business excellence, social impact, and sustainability.
  • Deloitte named Mary Kay Inc. one of the 2022 U.S. Best Managed Companies.

Product Stewardship

  • Achieved Forest Stewardship Council (FSC) certification (U.S.A only). The FSC certification ensures products come from responsibly managed forests providing environmental, social and economic benefits.
  • 12% of our indirect suppliers are women, minority or veteran-owned (U.S.A. only).
  • Achieved palm oil–88% certified and palm kernel–72% certified.
  • Held inaugural Sustainability-Focused Supplier Summit at global headquarters.
  • Named 2022 Silver Champion for Supplier Diversity & Inclusion.
  • Nominated and approved member of the steering committee for SPICE (Sustainable Packaging Initiative for CosmEtics).

Responsible Manufacturing

  • Supported The Arbor Day Foundation on three global reforestation projects in Brazil, Madagascar, and the United States.
  • Continued additional water usage analysis with plans to install new water flow meters.
  • Supported The Nature Conservancy’s Global Reefs program through 12 unique impact programs.
  • Joined the UN Global Compact’s Ocean Stewardship Coalition.
  • Richard R. Rogers Manufacturing/R&D facility (R3), announced it passed its OSHA VPP Star Re-Certification with zero findings and recommendations.
  • Received OSHA Star Re-Certification Credentials.

Women’s Empowerment

  • Published “Piloting SDG Localization at the Village Level: A Women-focused Poverty Reduction and Sustainable Development Project in Yunnan Province, China.” Impact Report (Phase 1: 2017-2021).
  • Completed The Women’s Empowerment Principles Gender Gap Analysis Tool as part of our participation in the UN Global Compact Target Gender Equality Accelerator.
  • Advanced women’s leadership in the fishing industry in Mexico through eight projects implemented by The Nature Conservancy.
  • Powered the global launch of a free Entrepreneurship Program in six languages, developed by International Trade Centre SheTrades Initiative.
  • Awarded 14 STEAM grants to young women around the world pursuing dreams in STEAM-related industries.
  • Joined the UN Global Compact Target Gender Equality Program to deepen implementation of the Women’s Empowerment Principles.
  • Submitted survey on the implementation of commitments across the Generation Equality Action Coalitions; findings reflected in UN Women’s Generation Equality Accountability Report 2022.

Social Impact

  • Since 2008, Pink Changing Lives has impacted more than six million women and their families by partnering with over 3,250 organizations and donating over $17 million. In 2022, the cause empowerment program supported over 20 NGOs around the world.
  • Mary Kay and the Mary Kay Ash Foundation grants supported the development and launch of a “GBV Guidance for Development Programs” and its rollout in 10 countries of intervention as well as the establishment of a Community of Practice convening 240 members across 16 countries to date.
  • Mary Kay and the Mary Kay Ash Foundation grants helped the UN Trust Fund change the lives of 54,822 women and girl survivors of violence through 157 GBV projects in 68 countries across five regions including women and girls living with disabilities, internally displaced or refugee women and girls, and Indigenous women and girls.
  • Donated more than $1.3 million to global organizations helping to enrich women’s lives.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn or follow us on Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005001/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye